Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Oncotarget|July 30, 2016
Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cellsAlice Nomura, Patricia Dauer, Vineet Gupta, et al.
Cancer Research|December 21, 2017
Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its RegressionPatricia Dauer, Xianda Zhao, Vineet K Gupta, et al.
Journal of Surgical Oncology|December 29, 2021
High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancerJennifer A Crozier, Julie Barone, Pat Whitworth, et al.
Scientific Reports|May 10, 2017
Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancerPatricia Dauer, Vineet K Gupta, Olivia McGinn, et al.
Cancer Letters|October 6, 2018
Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrityVineet Kumar Gupta, Nikita S Sharma, Kousik Kesh, et al.
Annals of Surgical Oncology|September 1, 2023
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant ChemotherapyPeter Blumencranz, Mehran Habibi, Steve Shivers, et al.
Theranostics|July 9, 2019
O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stabilityNikita S Sharma, Vineet K Gupta, Patricia Dauer, et al.
Surgical Oncology|November 27, 2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancerJames V Pellicane, Peter D Beitsch, David T Rock, et al.
JCO Precision Oncology|September 15, 2022
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant TherapyPat W Whitworth, Peter D Beitsch, Mary K Murray, et al.
Pageof 2